Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for stone expulsion after extracorporeal lithotripsy
IRCT20190624043991N47Phase 3Not yet recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of mirabegron in Lithiasis, nephrolithiasis and ureterolithiasis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Stone-free rate and Pain severity. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
mirabegron
03
Conditions
Lithiasisnephrolithiasisureterolithiasis
Beyond the preview
Go deeper on IRCT20190624043991N47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190624043991N47.